Dr. Ulrich Moebius has been appointed head of preclinical development and project management, MorphoSys. Dr. Moebius joins the company from Medigene AG, a German biopharmaceutical company, where for the last nine years, he held the position of head of preclinical development. He was responsible for the company's preclinical activities in a range of development projects predominantly in cancer, and contributed to the
market approval of two medical therapies.
Prior to Medigene, he spent five years with the Deutsches Krebsforschungszentrum DKFZ, Heidelberg, the leading German biomedical research institute dedicated to cancer research and two years at the Dana-Farber Cancer Institute in Boston, MA.
"I am delighted to welcome Dr. Moebius to the growing development team of MorphoSys. He combines broad academic research experience in multiple disciplines and indications, with an extensive drug development expertise in a biopharmaceutical company, which will support us in our plans to expand our proprietary drug pipeline," said Dr. Arndt Schottelius, chief development officer of MorphoSys AG.
"I'm looking forward to working with the entire R&D team of MorphoSys to expand the Company's proprietary pipeline and move new programs from research and discovery stage through pre-clinical development and into clinical trials quickly and efficiently," Dr. Moebius remarked.